priors.science/reviews/car-t-cell-therapy

CAR-T Cell Therapy

The current evidence on 11 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

11claims tracked
171primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
5 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
CAR-T versus autologous stem cell transplant, second-line diffuse large B-cell lymphoma (ZUMA-7/TRANSFORM)Dlbcl CartEstablished89%20
Ciltacabtagene progression-free survival in relapsed/refractory multiple myeloma (CARTITUDE-4)Myeloma CartEstablished89%18
Axicabtagene overall survival benefit in third-line-or-later diffuse large B-cell lymphoma (ZUMA-1)Dlbcl CartEstablished88%9
Tisagenlecleucel complete remission in paediatric B-cell acute lymphoblastic leukaemia (ELIANA)All CartEstablished86%19
Axicabtagene complete response in third-line-or-later follicular lymphoma (ZUMA-5)Indolent CartEstablished86%14
Idecabtagene overall response rate in triple-class refractory multiple myeloma (KarMMa)Myeloma CartEarly evidenceLikely84%17
Brexucabtagene minimal residual disease-negative mantle cell lymphoma (ZUMA-2)Indolent CartEarly evidenceLikely81%14
Cytokine release syndrome and neurotoxicity syndrome: predictors and management in CAR-TCart ToxicityLong-standingLikely81%8
Brexucabtagene in adult relapsed/refractory B-cell acute lymphoblastic leukaemia (ZUMA-3)All CartLikely80%15
Tisagenlecleucel overall survival in relapsed diffuse large B-cell lymphoma (JULIET)Dlbcl CartLikely77%20
CD19 antigen escape as CAR-T resistance mechanismCart ToxicityUncertain53%19
Track CAR-T Cell Therapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Early evidenceMost of this evidence is from the last two years.
Long-standingMost of this evidence is older than the rest of this field.